Back to trial detailsIntake questionnaire
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Applying to University of Nebraska Medical Center · Omaha, Nebraska
Answer a few short questions to share with the research team.
0 of 3 answered